See more : Stadio Holdings Limited (SDO.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- LION E-Mobility AG (LMIA.F) Income Statement Analysis – Financial Results
- Jiangxi Copper Company Limited (0358.HK) Income Statement Analysis – Financial Results
- Flowserve Corporation (0IQE.L) Income Statement Analysis – Financial Results
- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) Income Statement Analysis – Financial Results
- Scentre Group (SCG.AX) Income Statement Analysis – Financial Results
Cyclo Therapeutics, Inc. (CYTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyclotherapeutics.com
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | 1.01M | 1.24M | 1.50M | 950.46K | 1.57M | 1.69M | 1.04M | 1.03M | 802.37K | 623.87K | 494.94K | 751.18K | 542.31K | 454.36K | 464.69K | 394.53K | 522.37K | 289.43K | 384.59K |
| Cost of Revenue | 98.46K | 138.93K | 156.08K | 66.40K | 75.49K | 105.03K | 132.92K | 198.43K | 124.43K | 272.64K | 426.02K | 139.68K | 273.76K | 114.66K | 110.83K | 99.32K | 118.40K | 125.19K | 66.66K | 78.83K | 45.43K | 84.48K | 34.03K | 99.22K |
| Gross Profit | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | 906.45K | 1.10M | 1.30M | 826.03K | 1.29M | 1.27M | 905.27K | 758.09K | 687.71K | 513.04K | 395.62K | 632.77K | 417.13K | 387.70K | 385.87K | 349.10K | 437.89K | 255.40K | 285.37K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% | 89.62% | 89.26% | 86.80% | 86.91% | 82.61% | 74.84% | 86.63% | 73.47% | 85.71% | 82.24% | 79.93% | 84.24% | 76.92% | 85.33% | 83.04% | 88.48% | 83.83% | 88.24% | 74.20% |
| Research & Development | 14.18M | 9.00M | 9.15M | 6.10M | 4.87M | 2.71M | 2.29M | 1.86M | 658.51K | 94.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 7.81M | 6.50M | 3.68M | 3.43M | 2.43M | 2.62M | 2.64M | 2.22M | 1.53M | 639.54K | 560.17K | 799.60K | 678.64K | 693.33K | 520.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.90K | 13.06K | 18.34K | 5.01K | 5.89K | 5.64K | 7.85K | 7.16K | 7.57K | 10.90K | 8.91K | 10.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.83M | 7.82M | 6.52M | 3.68M | 3.44M | 2.44M | 2.63M | 2.65M | 2.23M | 1.55M | 648.45K | 570.98K | 799.60K | 678.64K | 693.33K | 520.06K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 548.79K |
| Other Expenses | 0.00 | 30.50K | 27.54K | 19.95K | 13.98K | 13.95K | 19.77K | 130.95K | 202.02K | 217.52K | 188.76K | 159.93K | 32.75K | 20.94K | 20.65K | 22.87K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Operating Expenses | 21.04M | 16.85M | 15.70M | 9.80M | 8.32M | 5.16M | 4.95M | 4.65M | 3.09M | 1.86M | 837.21K | 730.91K | 832.35K | 699.58K | 713.98K | 542.93K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Cost & Expenses | 21.13M | 16.99M | 15.85M | 9.86M | 8.40M | 5.27M | 5.08M | 4.85M | 3.22M | 2.13M | 1.26M | 870.59K | 1.11M | 814.24K | 824.81K | 642.25K | 557.51K | 475.86K | 566.97K | 743.61K | 308.93K | 325.02K | 313.14K | 674.43K |
| Interest Income | 0.00 | 12.47K | 3.41K | 19.80K | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.60K | 31.29K | 33.67K | 53.87K | 61.80K | 25.81K | 4.31K | 0.00 | 1.82K | 10.75K | 11.05K | 13.96K | 12.03K | 22.60K | 30.92K | 35.44K | 28.29K | |
| Depreciation & Amortization | 19.28K | 19.48K | 16.83K | 12.76K | 5.68K | 10.12K | 9.27K | 107.10K | 169.03K | 152.45K | 148.04K | 142.64K | 32.75K | 20.94K | 20.58K | 22.87K | 24.37K | 27.46K | 35.01K | 27.76K | 37.82K | 24.19K | 51.29K | 26.41K |
| EBITDA | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | -4.24M | -3.82M | -4.09M | -2.23M | -406.57K | 486.82K | 303.65K | -39.21K | 12.72K | -172.55K | -188.55K | 218.04K | -63.32K | -77.60K | -251.15K | 90.92K | 221.54K | 27.58K | -66.02K |
| EBITDA Ratio | -1,860.90% | -1,145.03% | -897.54% | -992.49% | -719.16% | -419.60% | -309.54% | -215.26% | -220.57% | -26.15% | 34.14% | 30.34% | -4.02% | 1.13% | -28.91% | -25.14% | 26.28% | 46.31% | -56.50% | 4.17% | 29.51% | 42.57% | 8.63% | -69.09% |
| Operating Income | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | -4.27M | -3.84M | -4.21M | -2.41M | -562.31K | 336.65K | 157.49K | -74.26K | -11.87K | -200.94K | -239.47K | 193.67K | -45.90K | -112.61K | -278.91K | 85.60K | 197.35K | -23.71K | -289.84K |
| Operating Income Ratio | -1,862.69% | -1,134.76% | -899.77% | -991.85% | -733.80% | -421.84% | -310.51% | -279.85% | -253.22% | -35.87% | 19.88% | 15.07% | -7.20% | -1.48% | -32.21% | -48.38% | 25.78% | -8.46% | -24.78% | -60.02% | 21.70% | 37.78% | -8.19% | -75.36% |
| Total Other Income/Expenses | -7.25K | 171.00K | 3.41K | 19.80K | 12.03K | 11.77K | 10.26K | -17.95K | -24.62K | -30.37K | -51.74K | -58.29K | -23.51K | -662.00 | 7.81K | 26.24K | 9.89K | -168.28K | 165.15K | -282.58K | -15.63K | -31.77K | -32.83K | 171.41K |
| Income Before Tax | -20.06M | -15.45M | -14.29M | -8.94M | -7.53M | -4.26M | -3.83M | -4.22M | -2.43M | -592.69K | 284.91K | 99.20K | -97.77K | -12.53K | -193.13K | -213.23K | 203.55K | -101.83K | 52.54K | -561.49K | 69.98K | 165.58K | -56.54K | -315.83K |
| Income Before Tax Ratio | -1,863.36% | -1,123.08% | -900.94% | -989.80% | -747.87% | -420.68% | -309.68% | -281.04% | -255.81% | -37.81% | 16.83% | 9.49% | -9.47% | -1.56% | -30.96% | -43.08% | 27.10% | -18.78% | 11.56% | -120.83% | 17.74% | 31.70% | -19.54% | -82.12% |
| Income Tax Expense | 0.00 | -171.00K | 18.52K | -18.53K | 141.75K | 11.77K | 0.00 | 28.60K | 120.00K | 33.67K | 80.00K | 25.00K | 25.81K | 25.00K | 0.00 | 200.00K | -450.00K | 168.28K | 225.00K | 282.58K | -225.00K | 31.77K | 90.17K | 195.00K |
| Net Income | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M | -4.26M | -3.83M | -4.22M | -2.55M | -592.69K | 204.91K | 74.20K | -97.77K | -37.53K | -193.13K | -413.23K | 653.55K | -101.83K | -172.46K | -561.49K | 294.98K | 165.58K | -113.88K | -510.83K |
| Net Income Ratio | -1,863.36% | -1,110.65% | -902.10% | -987.75% | -761.94% | -420.68% | -309.68% | -281.04% | -268.44% | -37.81% | 12.10% | 7.10% | -9.47% | -4.68% | -30.96% | -83.49% | 87.00% | -18.78% | -37.96% | -120.83% | 74.77% | 31.70% | -39.35% | -132.82% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| Weighted Avg Shares Out | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
| Weighted Avg Shares Out (Dil) | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM:...
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cyclo Therapeutics, Inc. (NASDAQ: CYTH) and Applied Molecular Transport Inc. is fair to Cyclo shareholders. Under the terms of the proposed transaction, Applied Molecular...
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport...
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the...
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the...
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott...
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD,...
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at...
Source: https://incomestatements.info
Category: Stock Reports